Does oseltamivir really reduce complications of influenza?

Clinical Infectious Diseases

Volumn 53, Issue 12, 2011, Pages 1302-1303

  Jones, Mark ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR;

BRONCHITIS; DRUG EFFICACY; HUMAN; INFECTION PREVENTION; INFLUENZA; LETTER; LOWER RESPIRATORY TRACT INFECTION; OTITIS MEDIA; PNEUMONIA; PRIORITY JOURNAL; SINUSITIS;

ANTIVIRAL AGENTS; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; OSELTAMIVIR; PNEUMONIA, BACTERIAL;

EID: 81855191155     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir706     Document Type: Letter

References (7)

1. Hernán MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011; Available at: http://www. ncbi.nlm.nih.gov/pubmed/21677258. Accessed 30 June 2011.
2. ECDC. Oseltamivir effective in reducing risk of some complications of flu. 2011. Available at: http://www.ecdc.europa.eu/en/activities/sciadvice/ Lists/ECDC%20Reviews/ECDC-DispForm.aspx?List5512ff74f-77d4-4ad8-b6d6- bf0f23083f30&ID51125&RootFolder5/en/activities/sciadvice/Lists/ ECDC%20Reviews& MasterPage51&PDF5true. Accessed 4 July 2011.
3. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667-72. (Pubitemid 36898954)
4. Hoffman-La Roche, Ltd. Product label. Tamiflu (oseltamivir phosphate) capsules and for oral suspension. 2010. Available from: http://www.accessdata. fda.gov/drugsatfda-docs/label/2010/021087s048s049,021246s034s035lbl. pdf. Accessed 13 September 2010.
5. Jefferson T, Doshi P, Thompson M, Heneghan C. Ensuring safe and effective drugs: who can do what it takes? BMJ 2011; 342: c7258.
6. Doshi P, Jefferson T, Thompson M, Heneghan C. Correction. BMJ Rapid Response 2011. Available at: http://www.bmj.com/content/342/bmj.c7258.full.html/ reply#bmj-el-248919. Accessed 30 June 2011.
7. Smith J. on behalf of Roche. Point-by-point response from Roche to BMJ questions. BMJ 2009; 339(dec083):b5374.